Oct 24, 2024 / 11:00AM GMT
Martin Amark - Xbrane Biopharma AB - Chief Executive Officer
Hello, everybody, and welcome to this webcast in relation to our quarterly report, the third quarter of 2024, Xbrane Biopharma. I am Martin Amark, the CEO, and I have with me also Anette Lindqvist, our CFO, in this call. We will, as usually, go through the highlights operationally and financially of the quarter, and then we will open up for questions, both via audio as well as on the chat.
So let's start here, and most of you who are calling in probably are aware of our business model. We are engaged in development of biosimilars. We have a portfolio that consists of four biosimilars and biosimilar candidates under development, all in all addressing reference product sales expected to reach about EUR26 billion by 2026.
Our first program, Ximluci, biosimilar to the eye drug Lucentis approved in Europe and launched in Europe since March 2023 by our partner STADA, and going through a regulatory process for approval in the US and subsequently post-approval to be launched by our US partner Valorum Biologics. We have, then, two
Q3 2024 Xbrane Biopharma AB Earnings Call Transcript
Oct 24, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers